Emergent BioSolutions Inc.
No enriched coverage for $EBS in the last 7 days.
No SEC Form 4 filings for $EBS in the last 30 days.
See all $EBS insider activity →Emergent BioSolutions (EBS) received a $24M contract modification from BARDA for its CYFENDUS anthrax vaccine, supporting national preparedness. The FDA-approved vaccine is used for post-exposure prophylaxis. EBS stock is up 0.82% at $6.15.
S&P Global Ratings revised Emergent BioSolutions' outlook to negative, citing lower revenue guidance due to competition in the naloxone market. The company reduced its 2026 revenue and EBITDA guidance by $80M and $25M, respectively, due to weaker NARCAN sales. S&P noted potential refinancing risks for Emergent's $440M unsecured notes maturing in 2028, with declining revenue and uncertain growth prospects.
Emergent BioSolutions (EBS) reported Q2 updates on its MCM and naloxone franchises. Management said MCM international sales were about 20% of first-half 2026 revenue. It received regulators’ approvals to expand ACAM2000 to Mpox. Due to NARCAN competition, EBS lowered 2026 revenue guidance to $645M-$675M and recorded a ~$191M non-cash impairment, plus ~$40M annualized cost savings.
Recent EBS coverage spans financial news, earnings and regulation.
The new contract provides additional revenue and underscores government reliance on Emergent's vaccine portfolio.
Negative outlook and guidance cuts raise refinancing risk into the Aug 2028 unsecured notes maturity.
Guidance cut plus a large NARCAN-related impairment and restructuring implies near-term earnings pressure and higher execution risk, but also cost actions to stabilize cash flows.
Restructuring savings may help future profitability, but the impairment and revenue dynamics raise near-term earnings quality concerns.
Near-term sentiment is mixed: revenue and adjusted metrics improved, but guidance cuts and large impairment plus restructuring charges raise downside risk.
AlphAI scores every news story that mentions EBS with an AI model for sentiment and relevance, and aggregates insider trades from Emergent BioSolutions Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Emergent BioSolutions (EBS) received a $24M contract modification from BARDA for its CYFENDUS anthrax vaccine, supporting national preparedness. The FDA-approved vaccine is used for post-exposure prophylaxis. EBS stock is up 0.82% at $6.15.
1 min readS&P Global Ratings revised Emergent BioSolutions' outlook to negative, citing lower revenue guidance due to competition in the naloxone market. The company reduced its 2026 revenue and EBITDA guidance by $80M and $25M, respectively, due to weaker NARCAN sales. S&P noted potential refinancing risks for Emergent's $440M unsecured notes maturing in 2028, with declining revenue and uncertain growth prospects.
4 min readEmergent BioSolutions (EBS) reported Q2 updates on its MCM and naloxone franchises. Management said MCM international sales were about 20% of first-half 2026 revenue. It received regulators’ approvals to expand ACAM2000 to Mpox. Due to NARCAN competition, EBS lowered 2026 revenue guidance to $645M-$675M and recorded a ~$191M non-cash impairment, plus ~$40M annualized cost savings.
6 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readEmergent BioSolutions (EBS) reported Q2 2026 revenue of $234.3 million, up 66% year over year, driven by accelerated U.S. government MCM contract modifications. Net loss widened to $180.2 million due to a $191.3 million non-cash Naloxone impairment. Adjusted EBITDA rose to $96.5 million. The company cut 2026 guidance and announced restructuring, including wet lab closures and about 93 job reductions.
5 min readEmergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS • Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year • Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million
6 min readEmergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. ebs-20260626 0001367644 false 0001367644 2026-06-26 2026-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
4 min readEmergent BioSolutions reported Q1 2026 revenue of $156 million, exceeding guidance, with an adjusted EBITDA of $36 million, driven by strong MCM performance and strategic international diversification. The company reduced its net debt by 22% in 2025 and aims for further improvement, while expanding its MCM business and pursuing accretive external opportunities, including a manufacturing partnership with SAB Biotherapeutics. Emergent also highlighted its continued leadership in the Narcan market and efforts to expand access and awareness for overdose prevention.
4 min readEmergent BioSolutions is expanding access to NARCAN® Nasal Spray by launching a new carrying case and multipack options, alongside a college campus outreach program. These initiatives aim to increase preparedness for opioid overdoses and reduce associated stigma, particularly among young adults. The company partnered with Pro Football Hall of Famer Emmitt Smith and Release Recovery Founder/CEO Zac Clark for an engagement at Southern Methodist University to promote awareness and education.
3 min readEmergent BioSolutions (NYSE: EBS) has secured over $60 million in new orders for smallpox medical countermeasures. This includes a $54 million contract option with the U.S. government for CNJ-016 (VIGIV) and $6.6 million in orders from an international government partner for ACAM2000. Additionally, the company referenced multi-year agreements with Canada valued up to $140 million CAD, with more than $35 million CAD expected in 2026.
2 min read
